Pulmonary Hypertension

Question 1

Question 1:
What is pulmonary hypertension, and what is the defining value for mean pulmonary artery pressure (mPAP) in this condition?

Answer 1

Answer:

Pulmonary hypertension is high blood pressure within the pulmonary circulation.

The defining value for mean pulmonary artery pressure (mPAP) in pulmonary hypertension is ≥ 25 mmHg.

Question 2

Question 2:
Differentiate between pulmonary hypertension and systemic hypertension.

Answer 2

Answer:

• Pulmonary hypertension is high blood pressure within the pulmonary circulation, while
• systemic hypertension is high blood pressure within the systemic circulation.

Question 3

Question 3:
What is Type I Pulmonary Artery Hypertension, and what are its key characteristics?

Answer 3

Answer:

• Type I Pulmonary Artery Hypertension is characterized by super vasoconstriction in the pulmonary vessels, leading to very high pulmonary vascular resistance.
• This results in an increase in mean pulmonary artery pressure (mPAP ≥ 25 mmHg) and puts strain on the right heart, leading to right ventricular hypertrophy and eventually right heart failure.

Question 4

Question 4:
What are the factors responsible for intense vasoconstriction in Type I Pulmonary Artery Hypertension?

Answer 4

Answer:

• intense vasoconstriction is caused by endothelin-1 (ET-1), a potent vasoconstrictor produced by endothelial cells.
• ET-1 causes smooth muscle contraction, leading to decreased vessel diameter, increased vasoconstriction, and increased peripheral vascular resistance.

Question 5

Question 5:
What are the factors responsible for decreased vasodilation in Type I Pulmonary Artery Hypertension?

Answer 5

Answer:
* result of reduced production of nitric oxide (NO) and prostacyclin (PGI2).

• Both NO and PGI2 act on smooth muscle and cause relaxation, increasing vessel diameter and decreasing peripheral vascular resistance.

Question 6

Question 6:
What are the etiological factors for Type I Pulmonary Artery Hypertension?

Answer 6

Answer:

(i) Idiopathic (most common, diagnosed by exclusion)
(ii) Hereditary - caused by the BMRR2 gene, leading to increased ET-1 production and decreased NO and PGI2 production
(iii) Connective tissue diseases, such as systemic lupus erythematosus (SLE) and scleroderma

(iv) HIV (mechanism not well-known)

(v) Porto-pulmonary hypertension, often seen in patients with cirrhosis, where liver failure leads to vasoactive molecules not being cleared, causing vasoconstriction and decreased vasodilation.

(vi) Left-to-right shunts, especially observed in infants with large ventricular septal defects (VSD), atrial septal defects (ASD), and patent foramen ovale.

Question 7

Question 1:
What are the two primary pathophysiological changes in pulmonary hypertension?

Answer 7

Answer:
increased vasoconstriction processes and decreased vasodilation processes.

Question 8

Question 2:
What is the consequence of increased peripheral vascular resistance in pulmonary hypertension?

Answer 8

Answer:
Increased peripheral vascular resistance in pulmonary hypertension leads to an increase in pulmonary artery pressure.

Question 9

Question 3:
How does pulmonary hypertension affect the right heart?

Answer 9

Answer:
Pulmonary hypertension puts strain on the right heart, leading to right ventricular hypertrophy and eventually right heart failure.

Question 10

Question 4:
List the different causes of pulmonary hypertension.

Answer 10

Answer:

(i) Idiopathic (most common)
(ii) Hereditary
(iii) Connective tissue diseases
(iv) HIV
(v) Porto-pulmonary hypertension
(vi) Left-to-right shunting

Question 11

Question 5:
What is Type II Pulmonary Artery Hypertension, and what are its common causes?

Answer 11

Answer:

• Type II Pulmonary Artery Hypertension is caused by left heart disease, including conditions such as left heart failure and valvular heart disease.

Question 12

Question 6:
What is the pathophysiological mechanism behind Type II Pulmonary Artery Hypertension?

Answer 12

Answer:

• In Type II Pulmonary Artery Hypertension, left heart disease causes an increase in pulmonary venous backflow from the left heart into the pulmonary vein.
• This leads to congestion in the pulmonary venous circulation, increasing pulmonary artery pressure and straining the right heart, ultimately resulting in right ventricular hypertrophy and right heart failure.

Question 13

Question 7:
Which lung diseases are associated with Type III Pulmonary Artery Hypertension?

Answer 13

Answer:
Type III Pulmonary Artery Hypertension is associated with underlying lung diseases, including:
(i) COPD (Chronic Obstructive Pulmonary Disease)
(ii) Interstitial lung disease
(iii) Obstructive sleep apnea
(iv) Obesity hypoventilation syndrome

Question 14

Question 8:
Explain the pathophysiological process of Type III Pulmonary Artery Hypertension in patients with lung diseases.

Answer 14

Answer:

• In Type III Pulmonary Artery Hypertension, inadequate ventilation in multiple lung parenchymal areas leads to hypoxic vasoconstriction.
• This causes pulmonary vessels to constrict, resulting in increased pulmonary vascular resistance and pulmonary artery pressure.
• The right heart is strained, leading to right ventricular hypertrophy and eventual right heart failure.

Question 15

Question 1:
What are the key characteristics of Type IV Pulmonary Artery Hypertension, and what is its primary cause?

Answer 15

Answer:

• Type IV Pulmonary Artery Hypertension is characterized by an increase in peripheral vascular resistance due to chronic pulmonary emboli (distal blood clots).
• Unlike Type III, which is due to hypoxia, Type IV’s increased vascular resistance is caused by clots obstructing blood flow.

Question 16

Question 2:
Explain the difference between vasoconstriction in Type I and Type IV Pulmonary Artery Hypertension.

Answer 16

Answer:
In Type I Pulmonary Artery Hypertension, vasoconstriction is due to increased levels of endothelin-1, while in Type IV, vasoconstriction occurs due to clots obstructing blood flow.

Question 17

Question 3:
Which lung diseases are associated with Type V Pulmonary Artery Hypertension?

Answer 17

Answer:
Type V Pulmonary Artery Hypertension is associated with lung diseases such as sarcoidosis, where granulomas compress the pulmonary vessels, and mediastinal tumors (e.g., tracheal, bronchial tumor, lymphoma) that compress the pulmonary artery.

Question 18

Question 4:
How does Type V Pulmonary Artery Hypertension affect the right heart?

Answer 18

Answer:
Type V Pulmonary Artery Hypertension increases pulmonary artery pressure, putting strain on the right heart, leading to right ventricular hypertrophy, and eventually, right heart failure.

Question 19

Question 5:
Summarize the primary causes and key characteristics of each type of Pulmonary Artery Hypertension.

Answer 19

Answer:

Type I: Idiopathic, increased vasoconstrictors (endothelin-1), decreased vasodilators (NO and PGI2).
Type II: Left heart disease, resulting in pulmonary venous backflow congestion.
Type III: Lung diseases causing hypoxic vasoconstriction.
Type IV: Chronic pulmonary emboli leading to increased peripheral vascular resistance due to clots.
Type V: Sarcoidosis or mediastinal tumors compressing the pulmonary artery.

Question 20

Question 1:
What are the classic clinical features of right heart failure in patients with pulmonary hypertension?

Answer 20

Answer:

• Jugular venous distention due to blood backing up into the superior vena cava and jugular vein.
• Ascites and hepatomegaly due to blood backing up into the liver through the inferior vena cava.
• Pedal edema caused by blood accumulating in the interstitial spaces of the lower extremities.

Question 21

Question 2:
How do auscultation findings differ between patients with systemic hypertension and pulmonary hypertension?

Answer 21

Answer:

• In patients with systemic hypertension, severe hypertension causes the aortic valve to snap hard, leading to a loud second heart sound (S2) with a particularly pronounced A2 component.
• In contrast, in patients with pulmonary hypertension, the high pulmonary pressure causes the pulmonary valve to close quickly during diastole, resulting in a loud S2 with a particularly pronounced P2 component.

Question 22

Question 3:
What is the primary cause of exertional dyspnea in patients with pulmonary hypertension?

Answer 22

Answer:

• Exertional dyspnea in patients with pulmonary hypertension is primarily due to the high pulmonary artery pressure,
• which leads to reduced blood flow through the pulmonary arterial circulation and decreased delivery of oxygen to the left heart,
• resulting in less left ventricular cardiac output and decreased oxygen delivery to the tissues.

Question 23

Question 4:
Why may patients with pulmonary hypertension experience exertional syncope?

Answer 23

Answer:

• Patients with pulmonary hypertension may experience exertional syncope due to inadequate oxygen delivery to the brain tissue during exertion, resulting from the high pulmonary artery pressure and reduced cardiac output.

Question 24

Question 5:
What is the most common exertional symptom in patients with pulmonary hypertension?

Answer 24

Answer:
Exertional dyspnea often leading to misdiagnosis as chronic heart failure or coronary artery disease.

Question 25

Question 1: What are the typical symptoms that should raise suspicion for pulmonary artery hypertension?

Answer 25

Answer: * exertional dyspnea, exertional syncope, and exertional angina. * Additionally, evidence of right heart failure due to high pulmonary pressure, such as right ventricular hypertrophy, should be considered.

Question 26

Question 2: What are the key classification criteria used to differentiate types of pulmonary artery hypertension?

Answer 26

Answer: Type I: Increased vasoconstrictors and decreased vasodilators. Type II: Left heart disease. Type III: Lung disease. Type IV: Chronic pulmonary emboli. Type V: Compression due to mediastinal tumor or sarcoidosis.

Question 27

Question 3: What is the primary purpose of performing an echocardiogram in the diagnostic approach to pulmonary artery hypertension?

Answer 27

Answer: * to rule out Type II Pulmonary Artery Hypertension, which is associated with left heart disease. * The echocardiogram can identify wall motion abnormalities, reduced ejection fraction, and valvular heart disease, and it helps to assess the right heart's structure and function.

Question 28

Question 4: What are the expected echocardiogram findings in patients with high pulmonary artery pressure?

Answer 28

Answer: * In patients with high pulmonary artery pressure, an echocardiogram is expected to show right ventricular hypertrophy initially. * Over time, evidence of right heart failure may become apparent, such as right ventricular dilation and right atrial enlargement.

Question 29

Question 5: Why might patients with pulmonary artery hypertension have exertional dyspnea?

Answer 29

Answer: due to high pulmonary artery pressure, leading to reduced blood flow through the pulmonary arterial circulation, decreased oxygen delivery to the left heart, and subsequently, less left ventricular cardiac output and oxygen delivery to the tissues.

Question 30

Question 1: What are the significant findings on the echocardiogram that suggest high right-sided pressures in pulmonary artery hypertension?

Answer 30

Answer: * right ventricular dilation, a little bit of hypertrophy, and significant right atrial enlargement. * The appearance of a plethoric inferior vena cava is also supportive of high right-sided pressure.

Question 31

Question 2: Why is a V/Q (Ventilation/Perfusion) scan preferred over a CTPA (Computed Tomography Pulmonary Angiography) in ruling out Type IV pulmonary artery hypertension due to chronic pulmonary emboli?

Answer 31

Answer: V/Q scans have been shown to be more effective in detecting chronic distal pulmonary emboli.

Question 32

Question 3: How does a high-resolution CT scan aid in the diagnostic approach to pulmonary artery hypertension?

Answer 32

Answer: * A high-resolution CT scan is helpful in ruling out Type III pulmonary artery hypertension and Type V pulmonary artery hypertension caused by mediastinal tumors or sarcoidosis. * It provides a detailed image of the lung parenchyma and mediastinum, allowing for the identification of pruning of the pulmonary arteries and dilation of the pulmonary arteries due to high pulmonary artery pressures.

Question 33

Question 4: What are the common features that may be observed in a chest X-ray regarding pulmonary artery hypertension?

Answer 33

Answer: * A chest X-ray may show features similar to a CT scan, but it might not be as detailed. * It can help identify cardiomegaly, enlargement of the pulmonary arteries, and signs of right heart strain.

Question 34

Question 5: Which diagnostic tests are helpful in ruling out specific types of pulmonary artery hypertension?

Answer 34

Answer: * Echocardiogram: Rules out Type II pulmonary artery hypertension and indicates right ventricular dilation and right atrial enlargement. * V/Q Scan: Rules out Type IV pulmonary artery hypertension due to chronic pulmonary emboli. * High-Resolution CT Scan: Helps rule out Type III and Type V pulmonary artery hypertension, as it provides detailed imaging of lung parenchyma and mediastinum.

Question 35

Question 1: What findings can be seen on chest X-rays or high-resolution CT scans in patients with pulmonary artery hypertension?

Answer 35

Answer: pruning of the pulmonary arteries (dilation) due to extremely high pulmonary artery pressure.

Question 36

Question 2: Why is a high-resolution CT scan preferred over a chest X-ray in the diagnostic approach to pulmonary artery hypertension?

Answer 36

Answer: because it provides more detailed imaging and allows for the evaluation of mediastinal tumors, sarcoidosis, COPD (obstructive lung disease), and interstitial lung disease (restrictive lung disease).

Question 37

Question 3: What is the role of a polysomnogram (sleep study) in the diagnostic approach to pulmonary artery hypertension?

Answer 37

Answer: A polysomnogram helps rule out Type III pulmonary artery hypertension caused by obstructive sleep apnea (OSA) or possibly associated obesity hypoventilation.

Question 38

Question 4: How can pulmonary function tests (PFTs) help differentiate between obstructive lung disease, restrictive lung disease, and pulmonary hypertension?

Answer 38

Answer: Obstructive lung disease: FEV1/FVC ratio < 70%, high total lung capacity (TLC), and residual volume (RV), and low DLCO (diffusing capacity of the lung for carbon monoxide). Restrictive lung disease: FEV1/FVC ratio ≥ 70%, very small TLC, RV, and functional vital capacity (FVC), and low DLCO. * Pulmonary hypertension: Normal FEV1/FVC ratio, normal TLC and RV, and decreased DLCO.

Question 39

Question 5: What does a decreased DLCO on PFTs suggest in patients with pulmonary hypertension?

Answer 39

Answer: * A decreased DLCO (diffusing capacity of the lung for carbon monoxide) on pulmonary function tests (PFTs) suggests pulmonary hypertension. * In the context of normal FEV1/FVC ratio, TLC, and RV, a decreased DLCO points toward the presence of pulmonary hypertension rather than obstructive or restrictive lung diseases.

Question 40

Question 1: What are some findings on an EKG that may suggest right heart strain in patients with pulmonary artery hypertension?

Answer 40

Answer: right ventricular enlargement, right ventricular hypertrophy, and right bundle branch block.

Question 41

Question 2: Which diagnostic tests help rule out specific causes of pulmonary artery hypertension?

Answer 41

Answer: * Liver function test (LFT): Rules out port-pulmonary hypertension due to cirrhosis. * HIV test: Helps rule out HIV-related pulmonary artery hypertension. * ANA (Antinuclear Antibody) test: Provides information about systemic lupus erythematosus. * Scleroderma antibodies: Assists in diagnosing scleroderma.

Question 42

Question 3: What is the role of right heart catheterization in the diagnostic approach to pulmonary artery hypertension?

Answer 42

Answer: * Right heart catheterization is performed to confirm the diagnosis of pulmonary artery hypertension after ruling out other types (Type II-V) and other potential causes. * It involves measuring the pulmonary artery pressure and pulmonary capillary wedge pressure to calculate the transpulmonary pressure gradient.

Question 43

Question 4: What does a high transpulmonary pressure gradient suggest in the context of pulmonary artery hypertension?

Answer 43

Answer: * A high transpulmonary pressure gradient, indicated by a high pulmonary artery pressure (mPAP ≥ 25mmHg) and low pulmonary capillary wedge pressure (< 15mmHg), suggests pulmonary artery hypertension. * This finding supports the diagnosis of Type I pulmonary artery hypertension, which is idiopathic or heritable in nature.

Question 44

Question 5: What diagnostic information does a high pulmonary capillary wedge pressure provide?

Answer 44

Answer: indicative of left atrial pressure and suggests Type II pulmonary hypertension, which is associated with left heart disease.

Question 45

Question 1: What is the primary treatment approach for Type I pulmonary artery hypertension?

Answer 45

Answer: focused on managing the underlying causes and associated conditions, such as HIV, porto-pulmonary hypertension, left-to-right shunt, scleroderma, and systemic lupus erythematosus.

Question 46

Question 2: How are other types of pulmonary artery hypertension (Type II-V) treated?

Answer 46

Answer: Type II: Treating the underlying left heart disease. Type III: Treating the underlying lung disease. Type IV: Treating the underlying chronic pulmonary emboli. Type V: Treating the underlying sarcoidosis or mediastinal tumor.

Question 47

Question 3: What is the rationale behind focusing on Type I pulmonary artery hypertension treatment?

Answer 47

Answer: * Type I pulmonary artery hypertension is idiopathic or heritable, and there may not be any specific underlying condition to target. * Thus, the treatment focuses on managing associated conditions that can contribute to pulmonary artery hypertension, such as HIV, porto-pulmonary hypertension, left-to-right shunt, scleroderma, and systemic lupus erythematosus.

Question 48

Question 1: What is the primary treatment approach for idiopathic Type I pulmonary artery hypertension?

Answer 48

Answer: reducing intense vasoconstriction and increasing vasodilation to decrease pulmonary vascular resistance, lower pulmonary artery pressure, and reduce the risk of right heart failure.

Question 49

Question 2: How is vasoreactivity tested in patients with idiopathic Type I pulmonary artery hypertension?

Answer 49

Answer: * Vasoreactivity is tested by giving patients vasodilators and assessing the response. * The goal is to determine if the vasodilator effectively dilates the pulmonary vessels, reducing mean pulmonary artery pressure.

Question 50

Question 3: What are the criteria for a positive vasoreactive test result in idiopathic Type I pulmonary artery hypertension?

Answer 50

Answer: * A positive vasoreactive test result includes meeting all three criteria: * Mean pulmonary artery pressure (mPAP) (absolute) < 40mmHg. * mPAP decrease > 10mmHg from the initial value after vasodilator administration. * Right ventricular cardiac output increases or stays the same.

Question 51

Question 4: What are the treatment options for patients with idiopathic Type I pulmonary artery hypertension who have a negative vasoreactive test?

Answer 51

Answer: * For patients with a negative vasoreactive test, treatment aims to increase vasodilation and decrease vasoconstriction. * This can be achieved through the use of medications that inhibit endothelin-1 receptors (endothelin-1 inhibitors -sentan), increase prostacyclin (prostacyclin analogs -prost-), or mimic nitric oxide action (PDE inhibitors -afil).

Question 52

Question 5: What precautions should be taken when using PDE inhibitors (phosphodiesterase inhibitors) to treat pulmonary artery hypertension?

Answer 52

Answer: When using PDE inhibitors like Sildenafil and Tadalafil to treat pulmonary artery hypertension, avoid giving nitrates or α-blockers simultaneously, as this can lead to a significant drop in blood pressure due to excessive vasodilation.

Question 53

Question: What is the last resort treatment option for refractory pulmonary artery hypertension?

Answer 53

Answer: a bilateral lung and heart transplant. This procedure involves removing the affected pulmonary vasculature from the lungs and replacing them with healthy ones, along with a fresh right heart to alleviate the severe impact of the disease.

Question 54

Question 1: What are the two main consequences of pulmonary hypertension?

Answer 54

Answer: * Strain on the right side of the heart trying to pump blood through the lungs. * Back pressure of blood into the systemic venous system.

Question 55

Question 2: Why does the pulmonary system have a low incidence of atherosclerosis?

Answer 55

Answer: due to its low pressure.

Question 56

Question 3: What are some causes of pulmonary venous hypertension?

Answer 56

Answer: Left ventricular systolic dysfunction Mitral regurgitation or stenosis Cardiomyopathy (e.g., alcohol, viral)

Question 57

Question 4: What are the main types of pulmonary arterial hypertension?

Answer 57

Answer: * Primary arterial hypertension (idiopathic or genetic). * Secondary arterial hypertension (occurs due to underlying diseases or known risk factors, such as heart disease or lung fibrosis).

Question 58

Question 1: What are the symptoms of pulmonary hypertension?

Answer 58

Answer: Fatigue Dyspnoea (shortness of breath) Chest pain Central cyanosis if hypoxic

Question 59

Question 2: What are the signs of pulmonary hypertension?

Answer 59

Answer: Dependent oedema Elevated JVP (jugular venous pressure) Right ventricular heave at the left parasternal edge Murmur of tricuspid regurgitation Loud P2 (second heart sound) Enlarged liver (pulsatile)

Question 60

Question 3: What investigations can be done to diagnose pulmonary hypertension?

Answer 60

Answer: * ECHO doppler to estimate systolic pulmonary arterial pressure Right heart catheterization to confirm the diagnosis * ECG (may show right ventricular hypertrophy, right axis deviation, and right bundle branch block) * CXR (may show cardiomegaly, dilated pulmonary arteries, and right ventricular hypertrophy) * NT-proBNP blood test (indicates right ventricular failure) * Ascultation may reveal a split second heart sound with a loud pulmonary component.

Question 61

Question 4: How is primary pulmonary hypertension treated?

Answer 61

Answer: with medications such as IV prostanoids (e.g., epoprostenol), * endothelin receptor antagonists (e.g., macitentan and bosentan), and * phosphodiesterase-5 inhibitors (e.g., sildenafil).

Question 62

Question 5: How is secondary pulmonary hypertension managed?

Answer 62

Answer: Secondary pulmonary hypertension is managed by treating the underlying cause, such as pulmonary embolism or systemic lupus erythematosus (SLE).

Question 63

Question 1: What is cor pulmonale?

Answer 63

Answer: * a condition of right heart disease that is secondary to lung disease. * It occurs due to chronic lung diseases such as COPD, fibrotic lung disease, or chronic ventilatory failure (e.g., obesity hypoventilation syndrome).

Question 64

Question 2: What causes cor pulmonale?

Answer 64

Answer: * Cor pulmonale is caused by lung diseases that lead to pulmonary hypertension. * For example, in COPD, there is a mismatch between ventilation and perfusion (V/Q ratio). * Hypoventilated alveoli cause vasoconstriction in the adjacent pulmonary vessels, leading to increased pressure on the pulmonary artery and subsequent pulmonary hypertension.

Question 65

Question 3: What are the pathological changes in cor pulmonale?

Answer 65

Answer: * right ventricular hypertrophy and dilation due to increased afterload caused by pulmonary hypertension. * This can eventually lead to right-sided heart failure.

Question 66

Question 4: Which lung diseases are commonly associated with cor pulmonale?

Answer 66

Answer: Cor pulmonale is commonly associated with chronic lung diseases such as COPD (Chronic Obstructive Pulmonary Disease), severe bronchiectasis, chronic bronchitis, and emphysema.

Question 67

Question 5: How does pulmonary hypertension contribute to cor pulmonale?

Answer 67

Answer: * Pulmonary hypertension increases the afterload on the right ventricle, leading to right ventricular hypertrophy and dilation. * As a result, the right heart becomes less efficient in pumping blood, eventually leading to right-sided heart failure in cor pulmonale.